Clinical Trial

A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to describe the treatment patterns and clinical outcomes of treatment with eltrombopag in primary immune thrombocytopenia (ITP) patients treated with prior corticosteroid therapy. This study will use secondary data provided by health care professionals (HCPs) for a sample of primary ITP patients, and primary data from a structured HCP survey. Data will be collected from HCPs working in various clinical centers across the United States (US), United Kingdom (UK), and Germany.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-25
notable Primary completion pushed: 2026-08-20 -> 2028-09-29 2026-06-16
minor Completion pushed: 2026-08-20 -> 2028-09-29 2026-06-16
Trial Details
NCT Number NCT07587723
Lead Sponsor Novartis Pharmaceuticals
Conditions Immune Thrombocytopenia
Enrollment 150 participants
Start Date 2026-06-25
Primary Completion 2028-09-29 (estimated)
Study Completion 2028-09-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-24